Beyond the CB1 Receptor: Is Cannabidiol the Answer for Disorders of Motivation?
Open accessThe DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
The Cannabis sativa plant has been used to treat various physiological and psychiatric conditions for millennia. Current research is focused on isolating potentially therapeutic chemical constituents from the plant for use in the treatment of many central nervous system disorders. Of particular interest is the primary nonpsychoactive constituent cannabidiol (CBD). Unlike Δ 9-tetrahydrocannabinol (THC), CBD does not act through the cannabinoid type 1 (CB1) receptor but has many other receptor targets that may play a role in psychiatric disorders. Here we review preclinical and clinical data outlining the therapeutic efficacy of CBD for the treatment of motivational disorders such as drug addiction, anxiety, and depression. Across studies, findings suggest promising treatment effects and potentially overlapping mechanisms of action for CBD in these disorders and indicate the need for further systematic investigation of the viability of CBD as a psychiatric pharmacotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Koob, G. F., & Volkow, N. D. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2009.110 · Cited by 5,340
Di Chiara, G., & Imperato, A. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.14.5274 · Cited by 4,733
Mechoulam, R., Ben-Shabat, S., Hanus, L., Ligumsky, M., Kaminski, N. E., Schatz, A. R., Gopher, A., Almog, S., Martin, B. R., Compton, D. R., et al. (1995) · Biochemical Pharmacology · doi:10.1016/0006-2952(95)00109-d · Cited by 2,913 · cited 1×
“The endogenous ligands Narachidonoylethanolamine (AEA) or anandamide (from the Sanskrit word ananda, meaning bliss) (Devane et al. 1992) and 2-arachidonoylglycerol (2-AG) (Mechoulam et al. 1995, Sugiura et al. 1995) were identified shortly thereafter.”
Determination and characterization of a cannabinoid receptor in rat brain
Devane, W. A., Dysarz, F. A., Johnson, M. R., Melvin, L. S., & Howlett, A. C. (1988) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09876-1 · Cited by 2,443 · cited 2×
“Following the isolation of THC from cannabis (Gaoni & Mechoulam 1964), researchers discovered that it binds to two different G protein–coupled receptors (GPCRs), the cannabinoid type 1 (CB1) (Devane et al. 1988) and CB2 (Munro et al.”
Cannabinoid receptor localization in brain.
Herkenham, M., Lynn, A. B., Little, M. D., Johnson, M. R., Melvin, L. S., de Costa, B. R., & Rice, K. C. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.5.1932 · Cited by 2,321 · cited 3×
“It is the most abundant GPCR in the brain (Mechoulam & Parker 2013), and consistent with its role in reward and cognition, its highest densities are in the basal ganglia, substantia nigra, globus pallidus, hippocampus, and cerebellum (Herkenham et al. 1990).”
2-Arachidonoylgylcerol: A Possible Endogenous Cannabinoid Receptor Ligand in Brain
Sugiura, T., Kondo, S., Sukagawa, A., Nakane, S., Shinoda, A., Itoh, K., Yamashita, A., & Waku, K. (1995) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1995.2437 · Cited by 2,196
Herkenham, M., Lynn, A., Johnson, M., Melvin, L., de Costa, B., & Rice, K. (1991) · The Journal of Neuroscience · doi:10.1523/jneurosci.11-02-00563.1991 · Cited by 2,159 · cited 1×
“However, dopamine neurons do not express CB1 receptors (Herkenham et al. 1991, Julian et al. 2003), and current data support a CB1 receptor–mediated increase in dopamine neuron activity due to local disinhibitory mechanisms (Lupica & Riegel 2005).”
THE EFFECTS OF STRESSFUL LIFE EVENTS ON DEPRESSION
Kessler, R. C. (1997) · Annual Review of Psychology · doi:10.1146/annurev.psych.48.1.191 · Cited by 2,111 · cited 1×
“…uthor M anuscript A uthor M anuscript A uthor M anuscript A uthor M anuscript Depression Stress is a predisposing factor for anxiety and depression (Kessler 1997), and many preclinical tests of depression involve acute or chronic stress and inescapable aversive stimuli and often induce both…”
The mesolimbic dopamine reward circuit in depression
Nestler, E. J., & Carlezon, W. A. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.09.018 · Cited by 2,059 · cited 1×
“This suggests a degree of potential overlap among the neurobiological mechanisms of these disorders, including disruptions of the mesolimbic reward circuitry and its interactions with other brain areas (Nestler & Carlezon 2006, Russo & Nestler 2013).”
The brain reward circuitry in mood disorders
Russo, S. J., & Nestler, E. J. (2013) · Nature Reviews Neuroscience · doi:10.1038/nrn3381 · Cited by 1,870 · cited 3×
“A uthor M anuscript A uthor M anuscript A uthor M anuscript A uthor M anuscript (Russo & Nestler 2013).”
Cited by
Cannabidiol: State of the art and new challenges for therapeutic applications
Pisanti, S., Malfitano, A. M., Ciaglia, E., Lamberti, A., Ranieri, R., Cuomo, G., Abate, M., Faggiana, G., Proto, M. C., Fiore, D., et al. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.02.041 · Cited by 614
Cannabidiol in Anxiety and Sleep: A Large Case Series
Shannon, S., Lewis, N., Lee, H., & Hughes, S. (2019) · The Permanente Journal · doi:10.7812/tpp/18-041 · Cited by 432
García-Gutiérrez, M. S., Navarrete, F., Gasparyan, A., Austrich-Olivares, A., Sala, F., & Manzanares, J. (2020) · Biomolecules · doi:10.3390/biom10111575 · Cited by 306
The endocannabinoid system as a target for novel anxiolytic drugs
Patel, S., Hill, M. N., Cheer, J. F., Wotjak, C. T., & Holmes, A. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.12.033 · Cited by 233
Self-citationVallée, A., Lecarpentier, Y., Guillevin, R., & Vallée, J.-N. (2017) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmx073 · Cited by 226
“CBD could not proceed by the CB1 receptor but possesses several other targets that can play a role in NDs or psychiatric disorders [218].”
Background
Metadata
- Authors
- Zlebnik, N. E., & Cheer, J. F.
- Venue
- Annual Review of Neuroscience
- Publisher
- Annual Reviews
- Published
- 2016-07-08
- Volume
- 39
- Issue
- 1
- Pages
- 1-17
- ISSN
- 0147-006X (ISSN-L)
- 1545-4126
- OpenAlex
- W2218751580
- Cited by
- 77
- References
- 49
- FWCI
- 1.42
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Beyond the CB1 Receptor: Is Cannabidiol the Answer for Disorders of Motivation? https://app.cochat.ai/papers/10.1146/annurev-neuro-070815-014038
- The paper
- Zlebnik, N. E., & Cheer, J. F. (2016). Beyond the CB1 Receptor: Is Cannabidiol the Answer for Disorders of Motivation? Annual Review of Neuroscience. https://doi.org/10.1146/annurev-neuro-070815-014038
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.